Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:05am, Thursday, 31'st Oct 2024
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion to Report Third Quarter 2024 Financial Results on November 7
08:00am, Thursday, 24'th Oct 2024
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Wednesday, 25'th Sep 2024
ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
12:30pm, Wednesday, 11'th Sep 2024
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Ins
Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment Conference
08:00am, Monday, 26'th Aug 2024
ANN ARBOR, Mich., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 26th Annual Global Investment Confer
Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs
09:10am, Monday, 19'th Aug 2024
Meeting expectations with revenue growth, expense guidance, and sales execution. Potential overhang from financial engineering with complex deals, warrants, and generic litigants. Maintaining a buy ra
Esperion Therapeutics: Strategically Positioned To Grow
04:09am, Friday, 16'th Aug 2024
Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving sign
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
09:50pm, Monday, 12'th Aug 2024
Esperion Therapeutics, Inc. (ESPR) Q2 2024 Earnings Call Transcript
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
12:47pm, Monday, 12'th Aug 2024
Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates.
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
08:11am, Monday, 12'th Aug 2024
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago.
Esperion Reports Second Quarter 2024 Financial Results and Provides a Business Update
06:00am, Monday, 12'th Aug 2024
– Total Revenue Increased 186% Year-over-Year to $73.8 Million with U.S. Net Product Revenue of $28.3 Million, Representing 39% Growth –
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Wednesday, 07'th Aug 2024
ANN ARBOR, Mich., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 7, 2024, the Company granted 18 new employees 66,800 restricted stock units (RSUs) under Espe
Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:01am, Monday, 05'th Aug 2024
Esperion Therapeutics (ESPR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) –
